<clinical_study>
<study_id>
<org_name>
  Lilly
</org_name>
<org_full_name>
  Eli Lilly and Company
</org_full_name>
<org_study_id>
  4015
</org_study_id>
<secondary_id>
  B9E-MC-JHQS
</secondary_id>
<nct_id>
  NCT00191100
</nct_id>
</study_id>
<brief_title>
<textblock>
  Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix
</textblock>
</brief_title>
<official_title>
<textblock>
  Phase 3 Randomized Comparison of Concurrent Gemcitabine, Cisplatin, and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Cancer of the Cervix Stages IIB to IVA
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Eli Lilly and Company
</agency>
</lead_sponsor>
</study_sponsor>
<oversight_info>
<regulatory_authority>
  Mexico: National Institute of Public Health, Health Secretariat
</regulatory_authority>
</oversight_info>
<brief_summary>
<textblock>
  The purpose of this study is to compare the effectiveness of two methods of treating cancer of the cervix. Half the patients will receive gemcitabine plus cisplatin while undergoing radiation therapy, followed by gemcitabine and cisplatin and the other half will receive cisplatin along with radiation therapy
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
Active, not recruiting  
</status>
<date>
2007-10 
</date>
</status_block>
<start_date>
<date>
  2002-05
</date>
</start_date>
<end_date>
<date>
</date>
</end_date>
<last_follow_up_date>
<date>
</date>
</last_follow_up_date>
<phase_block>
<phase>
  Phase 3
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Open Label
</design>
<design>
  Active Control
</design>
<design>
  Parallel Assignment
</design>
<design>
  Efficacy Study
</design>
<primary_outcome>
<measure>
  Overall survival - the expected median overall survival for the experimental arm is 78.6 months.
</measure>
<time_frame>
</time_frame>
</primary_outcome>
<secondary_outcome>
<measure>
  Time to progressive disease
</measure>
<time_frame>
</time_frame>
</secondary_outcome>
<secondary_outcome>
<measure>
  Local failure rate.
</measure>
<time_frame>
</time_frame>
</secondary_outcome>
<secondary_outcome>
<measure>
  Tumor response rate.
</measure>
<time_frame>
</time_frame>
</secondary_outcome>
<secondary_outcome>
<measure>
  Toxicity.
</measure>
<time_frame>
</time_frame>
</secondary_outcome>
<secondary_outcome>
<measure>
  - all performed at time of analysis for primary endpoint
</measure>
<time_frame>
</time_frame>
</secondary_outcome>
<enrollment>
  500
</enrollment>
<condition>
  Cancer of Cervix
</condition>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Gemcitabine
</primary_name>
<description>
<textblock>
</textblock>
</description>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Cisplatin
</primary_name>
<description>
<textblock>
</textblock>
</description>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
    - diagnosed with cancer of cervix
    - tumor that can be measured 
    - no previous treatment with chemotherapy or radiation for this cancer
    - able to give written consent
    - willing and able to participate in the study, both during the active treatment and the follow-up period.
 
  Exclusion Criteria:
    - impairment such as hearing loss from prior cisplatin therapy
    - damage to nerves such as being unable to distinguish hot and cold to touch
    - used other experimental medication in past 30 days
    - lab test results are not within the limits required for this study
    - pregnancy or breast-feeding or possibility of becoming pregnant during this study and not using an approved method of birth control.
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Female
</gender>
<minimum_age>
  18 Years
</minimum_age>
<maximum_age>
  70 Years
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Director
</role>
<name>
  Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
</name>
<affiliation>
<agency>
  Eli Lilly
</agency>
</affiliation>
</investigator>
<contact>
<name>
  There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
</name>
<phone>
  1-317-615-4559
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Buenos Aires
</city>
<state>
</state>
<zip>
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
Active, not recruiting  
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Sarajevo
</city>
<state>
</state>
<zip>
</zip>
<country>
  Bosnia and Herzegovina
</country>
</address>
</facility>
<status>
Active, not recruiting  
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Mumbai
</city>
<state>
</state>
<zip>
</zip>
<country>
  India
</country>
</address>
</facility>
<status>
Active, not recruiting  
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Mexico City
</city>
<state>
</state>
<zip>
</zip>
<country>
  Mexico
</country>
</address>
</facility>
<status>
Active, not recruiting  
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Karachi
</city>
<state>
</state>
<zip>
</zip>
<country>
  Pakistan
</country>
</address>
</facility>
<status>
Active, not recruiting  
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Lima
</city>
<state>
</state>
<zip>
</zip>
<country>
  Peru
</country>
</address>
</facility>
<status>
Active, not recruiting  
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Bangkok
</city>
<state>
</state>
<zip>
</zip>
<country>
  Thailand
</country>
</address>
</facility>
<status>
Active, not recruiting  
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<see_also>
<annotation>
<textblock>
  Lilly Clinical Trial Registry
</textblock>
</annotation>
<url>
  http://www.lillytrials.com
</url>
</see_also>
<initial_release_date>
  2005-09-12
</initial_release_date>
<last_release_date>
2007-10-18 
</last_release_date>
</clinical_study>
